Research Synthesis: Curcumin Inflammaging — full paper

Researka accepted publication: 2ed54f5a-fbc9-45ec-8fa9-5be79af12b17 Source submission: ae80f408-dcff-4aef-b15c-4036ac40e54a Inflammaging, the chronic low-grade inflammation that accompanies aging, is a key driver of age-related disease, and curcumin is a pleiotropic polyphenoid proposed to modulate this process (Xu 2025). This synthesis employed a structured, AI-assisted evidence review of 61 accepted reference papers to evaluate the clinical and mechanistic evidence for curcumin in the context of inflammaging, adhering to a transparent audit trail. However, the evidence base is heterogeneous; some trials report null effects on immune markers (Saleh 2025) or on neuropathic outcomes in diabetic patients (Mansour 2025), highlighting the importance of context and condition. Furthermore, a critical review found curcumin's efficacy is often limited by poor bioavailability, creating a tension between mechanistic promise and clinical realization (Xu 2025). The synthesis of cross-study disagreements across outcome classes, such as the severe disagreement on dosing pharmacokinetics (Wang 2025; Lamichhane 2025), underscores that the current evidence does not uniformly support a broad anti-aging claim. The evidence profile indicates that while curcumin demonstrates anti-inflammatory and cardiometabolic effects in specific clinical contexts, its role in combating systemic inflammaging remains incomplete and conditional on factors like bioavailability and population.